We performed a small-scale screening assay to identify FDA-approved compounds that reduce medulloblastoma cell viability and increase miR-33b expression using Daoy, a medulloblastoma cell line with an intact 17p11.2 and no gene amplification of MYC (Stearns et al, 2006). Here, MYC is linked to medulloblastoma.